FBR & Co Reiterates “Outperform” Rating for Rexahn Pharmaceuticals, Inc. (RNN)
Rexahn Pharmaceuticals, Inc. (NYSE:RNN)‘s stock had its “outperform” rating reiterated by stock analysts at FBR & Co in a report released on Thursday. They presently have a $3.00 target price on the stock.
Separately, Zacks Investment Research upgraded shares of Rexahn Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.25 price objective on the stock in a report on Friday, August 12th.
Shares of Rexahn Pharmaceuticals (NYSE:RNN) traded down 9.1500% on Thursday, reaching $0.1817. 2,780,388 shares of the company’s stock traded hands. The firm’s 50 day moving average is $0.23 and its 200 day moving average is $0.27. Rexahn Pharmaceuticals has a 52 week low of $0.18 and a 52 week high of $0.52. The firm’s market capitalization is $38.76 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/13/fbr-co-reiterates-outperform-rating-for-rexahn-pharmaceuticals-inc-rnn.html
Rexahn Pharmaceuticals (NYSE:RNN) last announced its quarterly earnings results on Monday, August 8th. The company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.02) by $0.01. Analysts expect that Rexahn Pharmaceuticals will post ($0.07) earnings per share for the current fiscal year.
An institutional investor recently raised its position in Rexahn Pharmaceuticals stock. Vanguard Group Inc. increased its stake in shares of Rexahn Pharmaceuticals, Inc. (NYSE:RNN) by 1.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,904,097 shares of the company’s stock after buying an additional 49,761 shares during the period. Vanguard Group Inc. owned about 2.30% of Rexahn Pharmaceuticals worth $1,232,000 at the end of the most recent quarter.
Rexahn Pharmaceuticals Company Profile
Rexahn Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company’s clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance.
Receive News & Ratings for Rexahn Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.